Differential Pharmacological Effects on Brain Reactivity and Plasticity in Alzheimer’s Disease

DSpace/Manakin Repository

Differential Pharmacological Effects on Brain Reactivity and Plasticity in Alzheimer’s Disease

Citable link to this page

 

 
Title: Differential Pharmacological Effects on Brain Reactivity and Plasticity in Alzheimer’s Disease
Author: Brem, Anna-Katharine; Atkinson, Natasha J.; Seligson, Erica E.; Pascual-Leone, Alvaro

Note: Order does not necessarily reflect citation order of authors.

Citation: Brem, Anna-Katharine, Natasha J. Atkinson, Erica E. Seligson, and Alvaro Pascual-Leone. 2013. “Differential Pharmacological Effects on Brain Reactivity and Plasticity in Alzheimer’s Disease.” Frontiers in Psychiatry 4 (1): 124. doi:10.3389/fpsyt.2013.00124. http://dx.doi.org/10.3389/fpsyt.2013.00124.
Full Text & Related Files:
Abstract: Acetylcholinesterase inhibitors (AChEIs) are the most commonly prescribed monotherapeutic medications for Alzheimer’s disease (AD). However, their underlying neurophysiological effects remain largely unknown. We investigated the effects of monotherapy (AChEI) and combination therapy (AChEI and memantine) on brain reactivity and plasticity. Patients treated with monotherapy (AChEI) (N = 7) were compared to patients receiving combination therapy (COM) (N = 9) and a group of age-matched, healthy controls (HCs) (N = 13). Cortical reactivity and plasticity of the motor cortex were examined using transcranial magnetic stimulation. Cognitive functions were assessed with the cognitive subscale of the Alzheimer Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), activities of daily living (ADLs) with the ADCS-ADL. In addition we assessed the degree of brain atrophy by measuring brain-scalp distances in seven different brain areas. Patient groups differed in resting motor threshold and brain atrophy, with COM showing a lower motor threshold but less atrophy than AChEI. COM showed similar plasticity effects as the HC group, while plasticity was reduced in AChEI. Long-interval intracortical inhibition (LICI) was impaired in both patient groups when compared to HC. ADAS-Cog scores were positively correlated with LICI measures and with brain atrophy, specifically in the left inferior parietal cortex. AD patients treated with mono- or combination-therapy show distinct neurophysiological patterns. Further studies should investigate whether these measures might serve as biomarkers of treatment response and whether they could guide other therapeutic interventions.
Published Version: doi:10.3389/fpsyt.2013.00124
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3791426/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:11878968
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters